Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Glaxo Zantac exclusivity extension runs through Aug. 29, unless Genpharm or Geneva win suits.

Executive Summary

GLAXO EXTENDED ZANTAC EXCLUSIVITY WILL RUN THROUGH AUG. 29 unless Genpharm or Geneva can prevail in separate litigation surrounding the effort to launch a generic version of ranitidine. Genpharm has been awarded exclusivity for generic ranitidine through Aug. 29, but cannot come to market until it prevails in litigation against Glaxo by proving that its form 1 ranitidine does not violate Glaxo's form 2 ranitidine patent, expiring in 2002. Geneva has filed a motion with the Fourth Circuit Court of Appeals for an injunction that all eligible manufacturers can bring generic ranitidine to market July 26; Geneva and Novopharm could market ranitidine if the court rules in its favor.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS030574

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel